CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications
Shots:
- LCB to receive $10 M as upfront- and up to $353.5M as cumulative milestone payments along with royalties on sales of LCB71. CStone get an exclusive global right to lead the development and commercialization of LCB71 outside the Republic of Korea
- The collaboration adds the first ADC to CStone's development pipeline- bolstering its precision medicine franchise with a new modality
- LCB71 is a pre-clinical ADC targeting ROR1- having the potential to treat multiple cancer indications and has demonstrated efficacy and reduced toxicity in preclinical studies
Ref: PRNewswire | Image: Investopedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com